Inhibitory effect of PI3Kδ inhibitor idelalisib on proliferation of human myeloid leukemia cells and the reversal effect on drug resistance to adriamycin.
10.11817/j.issn.1672-7347.2020.190728
- Author:
Kunlun LI
1
,
2
;
Pingyong YI
1
,
3
;
Hanjia LUO
1
,
3
;
Jiwei LI
1
,
3
;
Liu MENG
1
,
3
;
Min TANG
1
,
3
;
Weisi ZENG
1
,
3
;
Shuo YANG
1
,
3
;
Wei WANG
1
,
4
Author Information
1. Department of Geriatrics/Department of Gastroenterology and Urology Ward II, Hunan Cancer Hospital
2. Cancer Hospital Affiliated to Xiangya School of Medicine, Central South University, Changsha 410013, China. 1512920523@qq.com.
3. Cancer Hospital Affiliated to Xiangya School of Medicine, Central South University, Changsha 410013, China.
4. Cancer Hospital Affiliated to Xiangya School of Medicine, Central South University, Changsha 410013, China. wangweizzly@qq.com.
- Publication Type:Journal Article
- Keywords:
K562 cells;
K562/ADM cells;
idelalisib;
leukemia;
phosphatidylinositol 3-kinase/protein kinase B signal pathway;
reverse drug resistance;
tumor multiple drug resistance
- MeSH:
ATP Binding Cassette Transporter, Subfamily B, Member 1;
Cell Proliferation;
Doxorubicin/pharmacology*;
Drug Resistance, Multiple;
Drug Resistance, Neoplasm;
Humans;
K562 Cells;
Leukemia, Myeloid;
Purines;
Quinazolinones
- From:
Journal of Central South University(Medical Sciences)
2020;45(12):1389-1397
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To investigate the effect of adriamycin (ADM), idelalisib or ADM and their combination on cell proliferation and intracellular concentration of ADM, and to explore the reversal effect of idelalisib on drug resistance to ADM.
METHODS:The K562 and K562/ADM cells were respectively treated with ADM and idelalisib at different concentrations. The 50% inhibitory concentration (IC
RESULTS:The cell survival rates were significantly decreased in a dose-dependent manner when the cells were treated with different doses of ADM (0.001-10.000 mg/L ). The IC
CONCLUSIONS:Idelalisib exerts effect on inhibition of the proliferation in myeloid leukemia K562 and K562/ADM cells, which may partially reverse the drug resistance of K562/ADM cells to ADM. The mechanisms for the effect of idelalisib may be related to increasing the accumulation of ADM and inducing the cell apoptosis in the K562 and K562/ADM cells.
